Stay updated on DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma

Sign up to get notified when there's something new on the DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma page.
Latest website image capture
Clouds background image

Latest updates to the DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma page

  1. Check
    today
    Change Detected
    Summary
    The related topics section now includes 'Multiple myeloma' and 'MedlinePlus Genetics' as related topics. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-12-30T22:50:13.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    Added the Locations section with Attica, Greece (Athens site) to the study record. The revision note now shows Revision: v3.3.3, and older items like HHS Vulnerability Disclosure and Attica Locations were removed.
    Difference
    0.2%
    Check dated 2025-12-23T20:44:50.000Z thumbnail image
  3. Check
    14 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page no longer references 'Multiple myeloma' and the related MedlinePlus Genetics topics, removing core disease context from the study details.
    Difference
    0.2%
    Check dated 2025-12-09T14:18:11.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    Revision label updated from v3.2.0 to v3.3.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T10:36:15.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    Removed the government funding status notice and related operating-status details from the page. The related topics sections for 'Multiple Myeloma' and 'MedlinePlus Genetics' were also removed.
    Difference
    0.5%
    Check dated 2025-11-18T06:52:22.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    No significant content changes were detected between the two screenshots; core study details, eligibility criteria, and outcomes remain unchanged. Any observed differences appear to be formatting/layout adjustments rather than substantive updates.
    Difference
    0.5%
    Check dated 2025-11-03T20:44:53.000Z thumbnail image

Stay in the know with updates to DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma

Enter your email address, and we'll notify you when there's something new on the DARIA Trial: Daratumumab + Ixazomib in Multiple Myeloma page.